$NXGL News

NEXGEL Announces Data From Randomized, 30-Patient, Single-Center IRB Clinical Study, Funded By Innovative Optics

Nexgel (NXGL) Q1 2026 Earnings Transcript

NexGel Q1 2026 Earnings Call Transcript

NexGel Q1 EPS $(0.11) Misses $(0.07) Estimate, Sales $2.650M Miss $3.909M Estimate

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL Appoints Ian Blackman As CFO

NEXGEL Appoints Ian Blackman As CFO

NexGel shares are trading lower after the company announced the launch of BioNX Surgical. The company closed its previously announced license and and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity.

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

NEXGEL INC (NASDAQ:NXGL) Stock Plunges After Q4 2025 Earnings Miss

NexGel Q4 EPS $(0.12) Misses $(0.09) Estimate, Sales $2.796M Miss $3.240M Estimate

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

NEXGEL shares are trading lower. The company announced signing of a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity.

EXCLUSIVE: NEXGEL Signs To License, Acquire Portfolio Of Commercial-Stage Regenerative Biomaterial Products For ~$1.8M In Previously Announced Funding; Expected To Close ~$14.9M In Additional Financing In Early 2026

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

NEXGEL Announces $1.797M Funding Related To Potential Acquisition Targeted For Q1

Nexgel Appoints Adam E. Drapczuk III Interim CFO, Effective Jan. 1, Succeeding Joseph F. McGuire

NEXGEL, Inc.'s (NASDAQ:NXGL) Shift From Loss To Profit